Dry Eye Syndrome

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and
Market Analysis to 2022 th On 8 July 2014

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.
Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPointDry-Eye-Syndrome-Global-Drug-Forecast-and-Market-Analysis-118885

Scope
Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK,
Japan, China, and India
Annualized market revenues data
Each trend is independently researched to provide a qualitative analysis of its implications
Key topics covered include strategic competitor assessment, market characterization, unmet
Email ID- [e-mail]
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

needs and implications.

Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with
KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
*Model only available with site and global license purchases.

Key Findings
The global DES therapeutics market is forecast to reach $5.47 billion by 2022 due to the launch of novel pipeline drugs and an aging
Figure 4: Dry Eye Syndrome – Disease Etiology 16

Email ID- [e-mail]
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 5: Tear Film in Normal Eye and Dry Eye 17
Figure 6: 9MM, Prevalent Cases of Dry Eye Syndrome, Ages = 45 Years, Men and Women, N
(Millions), 2012–2022 31
Figure 7: 9MM, Prevalent Cases of Dry Eye Syndrome, By Age, N (Millions), 2012 33
Figure 8: 9MM, Prevalent Cases of Dry Eye Syndrome, By Sex, Ages = 45 Years, N (Millions),
2012 35
Figure 9: 9MM, Age-Standardized Prevalence of Dry Eye Syndrome, Ages = 45 Years, By Sex,
2012 36
Figure 10: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 40
Figure 11: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without
Lid Margin Disease, 2006 43
Figure 12: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid
Margin Disease and Abnormal Tear Distribution, 2006 44
Figure 13: Treatment Recommendations for Dry Eye Syndrome from the Management and
Therapy Subcommittee, Dry Eye Workshop, 2007 45
Figure 14: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011
46
Figure 15: Dry Eye Syndrome Therapeutics – Clinical Trials by Country, 2013